Is Corona Remedies’ IPO a compelling bet for long-term wealth creation?

Corona Remedies is set to raise ₹655.4 crore via an offer for sale. The company focuses on specialist doctors, driving faster revenue growth than the Indian pharmaceutical market. Its sales grew by 13.6% compared to the market's 7.9%. Revenue and net profit have shown strong annual growth. Investors with a high-risk appetite can consider this IPO for the long term.